Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community

Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yelamanchili R

Authors: Radhika Y, Chan D, Thawer A, Lo D, Singh S,

Keywords: Shared care, NET, Local Medical Oncologists, NET specialty centers,

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#3070 Activity and Safety of Avelumab in Merkel Cell Carcinoma: Our Experience

Introduction: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The use of checkpoint inhibitors has shown good results in the treatment of advanced MCC. Avelumab is a PD-L1 inhibitor able to prevent the inactivation of the T lymphocytes. We report a serie of consecutive MCC cases treated with Avelumab in two centres

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Giuffrida D

Authors: Puliafito I, Sciacca D, Bonasera A, Blanco G, Iacono F,

Keywords: mcc, avelumab, activity, safety,